ArticleEuropean journal of nuclear medicine and molecular imaging2018
Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2025Review
- The role of FET-PET in patient selection and response assessment for reirradiation in recurrent glioblastoma.Frontiers in oncology · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Therapeutic potential of tumor treating fields for malignant brain tumors.Cancer reports (Hoboken, N.J.) · 2023Review
- Nuclear Medicine Imaging Procedures in Oncology.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [Neoplasia (New York, N.Y.) · 2021Article
- TERT-Promoter Mutational Status in Glioblastoma - Is There an Association With Amino Acid Uptake on DynamicFrontiers in oncology · 2021Article
- Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors.Molecules (Basel, Switzerland) · 2020Review
- Prognostic Value of O-(2-[Molecular imaging and biology · 2019Article
- Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Review
- Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe present our first clinical experience with O-(2-
methodsWe retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBR
resultsIn all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBR
conclusionFET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields.
Indexed as
Identifiers
29564490What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.